Sat, Apr 13, 2013 - Page 4 News List

NHRI prepared for bird flu emergency

OPEN QUESTIONS:Despite an ability to mass-produce an H7N9 vaccine in months, there remains doubt regarding which variant of the virus would be used as a model

By Alison Hsiao  /  Staff reporter

Adimmune Corp chairman Steve Chan speaks at a press conference yesterday, saying that his company is the only Taiwanese manufacturer certified to produce vaccines that meet the Department of Health’s CGMP and PIC/S standards.

Photo: CNA

The National Health Research Institutes (NHRI), a nonprofit foundation established by the government, yesterday said it could produce 200,000 doses of a vaccine against the new H7N9 strain of avian flu within three months in the event of an emergency.

“The NHRI could support Department of Health policies to fight disease by producing vaccines if there were an emergency,” Su Ih-jen (蘇益仁), director of the NHRI’s National Institute of Infectious Diseases and Vaccinology, said at a meeting called by the Taiwan Solidarity Union (TSU) at which the department gave a briefing on H7N9 bird flu vaccines.

The health department reported it has sent out requests to the US Centers for Disease Control and Prevention (CDC), the WHO and China for the vaccine strain or the virus strain, and have so far secured the US CDC’s preliminary consent to access its H7N9 virus strain.

The department said it takes approximately two months to prepare a vaccine from the H7N9 virus strain, another six months for mass production of the vaccine by domestic vaccine manufacturers, and time would also be needed before the final market authorization could be granted by the health authorities.

Deputy Department of Health Minster Lin Tzou-yien (林奏延) said the first batch of H7N9 vaccine produced, expected to be 300,000 or 500,000 doses, would be provided to disease-control workers, frontline healthcare workers and poultry farmers.

“We would be able to use reverse genetics technology to prepare a vaccine seed strain [from the H7N9 virus strain] if necessary, even though this would be our very first,” Lin said.

Su confirmed the institute’s ability, but added that there is still the question of which of the H7N9 virus strains would be offered.

“There are differences in the strains discovered in the four H7N9-affected regions in China, and we hope China can provide more information on the adaption of the virus strains. A vaccine based on the earliest-discovered virus strain would likely prove to be the most effective,” he said.

TSU lawmakers at the meeting reiterated their skepticism about cross-strait cooperation on the vaccine production.

“Undertaking a vaccine production project hand-in-hand with a country aiming more than a thousand missiles at Taiwan would be ludicrous,” TSU caucus whip Lin Shih-chia (林世嘉) said.

“It’s possible that the reason China has delayed providing the virus strain is out of commercial or political concern, for fear that we might successfully develop the vaccine ahead of them,” TSU Legislator Hsu Chung-hsin (許忠信) said.

Discussing Taiwan’s situation of being denied access to vaccines and other benefits promised by the Pandemic Influenza Preparedness Framework for WHO member states, Lin urged the government to continue its efforts to join the organization instead of being content with observer status at the World Health Assembly.

Additional reporting by CNA

This story has been viewed 2308 times.

Comments will be moderated. Remarks containing abusive and obscene language, personal attacks of any kind or promotion will be removed and the user banned.

TOP top